Aleteia logoAleteia logo
Aleteia
Monday 02 August |
Saint of the Day: St. Peter Julian Eymard
home iconLifestyle
line break icon

Could testosterone be the key to curing prostate cancer?

Eduardo García Cruz CC

Zoe Romanowsky - published on 12/02/16

A new study from Johns Hopkins shows a breakthrough in one of the leading cancers in men

About one man in seven will be diagnosed with prostate cancer in his lifetime. According to the American Cancer Society’s estimates for prostate cancer in for 2016, about 180,890 new cases of prostate cancer will have been diagnosed this year, and about 26,120 men will have died.

But some promising results of a new study at out of the Johns Hopkins University School of Medicine were just made public: A man with advanced prostate cancer is believed to be cured after his tumor was  “shocked to death” with large amounts of testosterone. And other gravely ill men in the same study have shown remarkable improvement. These results were completely unexpected by experts, as leading prostate cancer therapies to date were based on depriving tumors of testosterone since cancer can use it as a fuel.

“We are still in the early stages of figuring out how this works and how to incorporate it into the treatment paradigm for prostate cancer. Many of the men have stable disease that has not progressed for more than 12 months. I think we may have cured one man whose PSA dropped to zero after three months and has remained so now for 22 cycles. His disease has all disappeared,” says Professor Sam Denmeade who led the study.

The Telegraph reports that all the patients in the study had cancer that was spreading and resistant to two common hormone therapy drugs.

According to the article, for decades now, advanced prostate cancer patients were treated by cutting off the supply of testosterone — or blocking its effects. But lab experiments had nevertheless shown that tumors responded to being blasted with high levels of the hormone. The treatment doctors used in the new trial involved “three cycles of bipolar androgen therapy (BAT) which involves alternately flooding and starving the body of the male hormone testosterone.” The men were injected with high doses of  testosterone once every 28 days, while at the same time they were given a drug that stopped the testicles from naturally producing testosterone.

The treatment worked, but it’s still not clear exactly how. Researchers want to see further studies to better understand  how it works, but all agree that it’s very promising.

Tags:
Science
Support Aleteia!

If you’re reading this article, it’s thanks to the generosity of people like you, who have made Aleteia possible.

Here are some numbers:

  • 20 million users around the world read Aleteia.org every month
  • Aleteia is published every day in seven languages: English, French, Italian, Spanish, Portuguese, Polish, and Slovenian
  • Each month, readers view more than 50 million pages
  • Nearly 4 million people follow Aleteia on social media
  • Each month, we publish 2,450 articles and around 40 videos
  • We have 60 full time staff and approximately 400 collaborators (writers, translators, photographers, etc.)

As you can imagine, these numbers represent a lot of work. We need you.

Support Aleteia with as little as $1. It only takes a minute. Thank you!

Daily prayer
And today we celebrate...




Top 10
1
SIMONE BILES
Cerith Gardiner
Simone Biles leaves the Olympics with an important lesson for her...
2
Ignacio María Doñoro
Francisco Veneto
The military chaplain who pretended to be a criminal to rescue a ...
3
HIDILYN DIAZ
Cerith Gardiner
Gold-winning Filipina Olympian shares her Miraculous Medal for th...
4
JEDZENIE
Theresa Civantos Barber
The one thing we all should do before this summer ends
5
Zelda Caldwell
German women’s gymnastics teams modest dress protests sport’s ...
6
CARLO ACUTIS
Violeta Tejera
Carlo Acutis’ first stained glass window in jeans and sneak...
7
Zelda Caldwell
World-record winning gymnast Simone Biles leans on her Catholic f...
See More
Newsletter
Get Aleteia delivered to your inbox. Subscribe here.